bromocriptine / Generic mfg. - LARVOL DELTA

Neuroleptic Malignant Syndrome on Chronic Trifluoperazine Therapy: A Diagnostic Dilemma. (PubMed, Clin Case Rep) - "Neuroleptic malignant syndrome (NMS) is a rare, life-threatening reaction to antipsychotic medication. The patient's condition improved following supportive care, administration of bromocriptine, and lorazepam. This case highlights the diagnostic challenges of NMS in patients on a stable antipsychotic regimen and underscores the importance of early recognition, particularly after excluding infectious etiologies."

Journal • CNS Disorders • Infectious Disease • Septic Shock

Hyperprolactinemia and migraine-like headache: A case report and literature review (EHF-EHC 2025) - "She was treated with bromocriptine for three months, achieving complete headache resolution...Repeat MRI showed a pituitary microadenoma, and cabergoline was reinitiated, with significant headache improvement...Eletriptan was prescribed for acute attacks...Dopamine agonists may relieve symptoms, even without tumor shrinkage, indicating a hormonal component. Pituitary hormones like PRL and hypothalamic peptides such as oxytocin may underlie sex differences in migraine.Endocrine evaluation is advised in refractory or atypical headache cases."

Case report • Clinical • Review • CNS Disorders • Endocrine Disorders • Gynecology • Migraine • Pain

Cardiovascular Disease in Pregnancy: When Two Hearts Beat as One. (PubMed, Diagnostics (Basel)) - "Content: The discussion centers on three high-impact clinical domains: (1) peripartum and preexisting cardiomyopathies, emphasizing mechanisms, prognosis, and the role of bromocriptine; (2) anticoagulation management in women with mechanical prosthetic valves, balancing maternal safety and fetal protection; and (3) hypertensive disorders of pregnancy, highlighting recent evidence from the CHAP and WILL trials and their implications for long-term cardiovascular prevention...Perspectives: Endothelial dysfunction, angiogenic imbalance, and systemic inflammation emerge as shared mechanisms linking diverse pregnancy-related cardiovascular conditions. Strengthening multidisciplinary care through Pregnancy Heart Teams, integrating obstetric and cardiologic expertise, and establishing structured postpartum follow-up pathways are essential to improve outcomes."

Journal • Review • Cardiomyopathy • Cardiovascular • Hypertension • Inflammation • Obstetrics

Bromocriptine, Selegiline and Amantadine in the Treatment of Depression-A Systematic Review. (PubMed, Pharmaceuticals (Basel)) - " Findings suggest that bromocriptine, amantadine, and selegiline may represent effective dopaminergic antidepressants, particularly for treatment-resistant or atypical depression. Further large-scale, methodologically rigorous studies are needed to confirm their clinical utility."

Journal • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry

Therapeutic challenges of giant invasive cystic macroprolactinoma. (PubMed, Endocrinol Diabetes Metab Case Rep) - "Postoperatively, despite sequential treatment with bromocriptine and cabergoline (maximum approved dose of 3 mg/week), prolactin levels failed to normalize. Dopamine agonists remain the first-line therapy for both giant and cystic prolactinomas. Early surgical intervention is indicated for vision-threatening conditions or in cases of dopamine agonist resistance."

Journal • Endocrine Disorders • Oncology • Pituitary Gland Carcinoma • PRL

Gestational Gigantomastia: A Century of Evidence with a New Case. (PubMed, Plast Reconstr Surg Glob Open) - "First-line medical therapy (bromocriptine, cabergoline, or norethindrone) achieved partial arrest in approximately 35% of trials; definitive control required surgery in 57% (reduction mammaplasty 29%, mastectomy 28%). Early recognition, prompt endocrine modulation, and timely, staged surgery are critical. We provide the largest curated dataset to date, quantify the mortality risk, and propose a stepwise management algorithm to guide multidisciplinary teams confronting this formidable obstetric challenge."

Journal • Hematological Disorders • Infectious Disease • Obstetrics • Septic Shock

Dopamine Action on Metabolism in Relation to Genotype (clinicaltrials.gov) - P2 | N=120 | Completed | Sponsor: University Hospital Tuebingen | Recruiting ➔ Completed

Heterogeneity • Trial completion • Genetic Disorders • Obesity • FTO

Pregnancy-Associated Cardiomyopathy in a Late-Diagnosed Partial Hydatidiform Mole: A Case Report. (PubMed, Case Rep Obstet Gynecol) - "Particularly, if cardiac symptoms occur, early diagnosis should be carried out. Close cardiological and gynecological follow-up must be carried out to prevent late complications."

Journal • Acute Kidney Injury • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Endocrine Disorders • Gestational Trophoblastic Neoplasia • Heart Failure • Infectious Disease • Metabolic Disorders • Oncology • Pneumonia • Renal Disease • Respiratory Diseases

Advances in biomarker discovery for peripartum cardiomyopathy: current status and future directions. (PubMed, Expert Rev Cardiovasc Ther) - "Cathepsin D shows therapeutic potential, while miR-146a offers an alternative to bromocriptine without lactation suppression...Multi-marker strategies are essential to address PPCM heterogeneity and improve diagnostic accuracy. Future research should validate these biomarkers, refine diagnostic tools, and explore therapeutic applications to transform PPCM management and outcomes."

Biomarker • Journal • Review • Cardiomyopathy • Cardiovascular • CNS Disorders • Congestive Heart Failure • Gynecology • Heart Failure • Infectious Disease • CTSD • MIR146A • QSOX1

Clinical practice considerations on cabergoline in the treatment of pituitary prolactinoma (PubMed, Zhonghua Yi Xue Za Zhi) - "Cabergoline, a selective D2 receptor agonist with high receptor affinity and long-acting properties, is recommended as a first-line treatment in international guidelines for prolactinoma management.Based on the 2014 edition, the "Consensus on the diagnosis and treatment of pituitary prolactinoma (2025 edition)" has made important updates to the treatment recommendations for cabergoline, mainly including: For patients with bromocriptine resistance, if cabergoline is available, switching to cabergoline is recommended as the first choice; For patients receiving long-term, high-dose cabergoline treatment, regular echocardiogram monitoring is recommended to assess the condition of heart valves. However, since cabergoline has not yet been marketed in Chinese mainland, the practical clinical experience with this drug in the domestic setting remains relatively limited, and there is a lack of systematic summary of local data. Endocrinologists need to pay special..."

Journal • Cardiovascular • Neuroendocrine Tumor • Oncology • Solid Tumor

In Silico Electrophysiology and System Pharmacology: Coupling Between Dopamine Receptors and Ca²⁺ Channels in Subthalamic Neuronal Cells in Parkinson's Disease with Statistical Data Analysis (Neuroscience 2025) - "Pharmacological intervention was simulated using the D2R agonist Bromocriptine (10 µM)... This study presents a robust computational and statistical approach to analyzing the coupling between D2Rs and N-type Ca²⁺ channels in STN neurons. The findings suggest that D2R activation dampens neuronal excitability via calcium channel inhibition, contributing to the hypoactivity observed in PD. These insights support the potential for therapeutic strategies targeting ion channel dynamics, beyond traditional dopamine replacement, and offer a validated framework for future studies in neuropharmacology and systems neuroscience."

CNS Disorders • Movement Disorders • Parkinson's Disease • DRD2

Bromocriptine in peripartum cardiomyopathy: A meta-analysis with trial sequential analysis. (PubMed, ESC Heart Fail) - "In this meta-analysis with TSA, the use of bromocriptine with standard care was associated with improved LV function and remodelling in patients with PPCM compared with standard care alone, with a similar effect on mortality and re-hospitalization. TSA indicated that current evidence is promising, but larger and adequately powered randomized trials are needed to confirm bromocriptine's cardioprotective effects."

Journal • Retrospective data • Review • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Drug discovery research with the iPSC models of neurodegenerative diseases. (PubMed, Neurosci Res) - "In addition, clinical trials based on research with iPSCs have been conducted: bosutinib, ropinirole and ezogabine for ALS, WVE-004 and BIIB078 for ALS with frontotemporal dementia (ALS/FTD), and bromocriptine for familial AD. Finally, we also wish to mention screening studies utilizing artificial intelligence (AI)."

Journal • Review • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Dementia • Frontotemporal Lobar Degeneration

Virtual screening of drugs against multiple targets of Alzheimer's disease. (PubMed, J Alzheimers Dis) - "BackgroundDrug repurposing offers a rapid, cost-effective approach for discovering therapies against multiple targets.ObjectiveHere, we screen virtual ligand libraries consisting of 3468 approved drugs against 11 protein targets associated with Alzheimer's disease (AD).MethodsWe employ blind molecular docking, and target amyloid-β (Aβ), microtubule-associated protein tau (MAPT), Apolipoprotein E4 (APOE4), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), amyloid-β protein precursor (AβPP), β-secretase (BACE1), brain-derived neurotrophic factor (BDNF), presenilin 1 (PSEN1) and 2 (PSEN2), and α-synuclein (SNCA) proteins using AutoDock Vina.ResultsNotably, multitarget binding recurs among the top-10 ligands with Ergotamine and Dihydroergotamine potentially binding 8; Dutasteride 7; Drospirenone and Nilotinib 6; Adapalene and Conivaptan 5; Bromocriptine 4; and Rolapitant, Irinotecan, Plerixafor, Saquinavir, and Telmisartan 3, out of 11 protein targets. Likewise,..."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Hypertension • Inflammation • Pain • APOE • BDNF • MAPT • SNCA

Letter to the editor: "Evaluation of bromocriptine for the reduction of fever in patients with acute neurologic injury: A retrospective cohort study". (PubMed, J Crit Care) - No abstract available

Journal • Retrospective data

Effect of bromocriptine mesylate on the patients of polycystic ovary syndrome (ChiCTR) - P4 | N=120 | Recruiting | Sponsor: Sir Run Run Hospital, Nanjing Medical University; Sir Run Run Hospital, Nanjing Medical University

New P4 trial • Polycystic Ovary Syndrome • HP

Metabolic Parkinson's disease. (PubMed, Front Aging Neurosci) - "Notably, antidiabetic drugs like metformin and incretin mimetics have shown beneficial effects in PD due to their neuroprotective and anti-inflammatory properties, their ability to restore insulin sensitivity, and their role in reducing neuronal susceptibility to toxic insults, as demonstrated in both preclinical and clinical studies. Conversely, traditionally antiparkinsonian drugs such as bromocriptine have long been approved for improving glycemic control in diabetes. This cross-efficacy between drugs used for the two conditions may indirectly support the hypothesis of a shared pathogenesis. A deeper understanding of the connections between metabolic disorders and PD could pave the way for novel preventive and therapeutic strategies."

Journal • Review • CNS Disorders • Diabetes • Genetic Disorders • Inflammation • Metabolic Disorders • Movement Disorders • Obesity • Parkinson's Disease • Type 2 Diabetes Mellitus

DOUBLE TROUBLE: CONCURRENT SEROTONIN SYNDROME AND NEUROLEPTIC MALIGNANT SYNDROME (CHEST 2025) - "Bottles of paroxetine and olanzapine were found at the scene...The patient was intubated for airway protection and initiated on intravenous midazolam...Dantrolene for severe muscle rigidity and bromocriptine, a dopamine receptor agonist, are indicated in severe cases of NMS... This case demonstrates the importance of maintaining a high clinical suspicion for both NMS and SS in patients presenting with hyperthermia who are on multiple psychotropic medications. The temporal course of symptoms and response to specific therapies can help distinguish between these syndromes, even when initial presentation is ambiguous."

Cardiovascular • CNS Disorders • Depression • Epilepsy • Heart Failure • Major Depressive Disorder • Mood Disorders • Movement Disorders • Ophthalmology • Psychiatry

Curcumin for the treatment of pituitary adenomas: the potential of a single agent for multifaceted therapeutic effects. (PubMed, Front Endocrinol (Lausanne)) - "Synergistic effects enhance existing therapies: low-dose curcumin potentiates bromocriptine in prolactinomas by regulating ERK/EGR1 and AKT/GSK-3β, while in aggressive PAs, it may overcome temozolomide resistance by downregulating DNA repair enzymes. Curcumin's ability to concurrently target tumor growth, hormone hypersecretion, and metabolic complications positions it as a unique "one drug, multiple effects" candidate. Future research must prioritize PA-specific mechanistic studies and advanced delivery systems to realize its clinical potential."

Journal • Review • Endocrine Disorders • Metabolic Disorders • Oncology • Osteoporosis • Pituitary Gland Carcinoma • EGR1 • HIF1A • MMP9

Function and mechanism of dopamine receptor D2 (DRD2) in neuroinflammation and behavioral disorders in C57BL/6J mice infected with Toxoplasma gondii TgCtWh6 strain. (PubMed, Brain Behav Immun) - "Furthermore, the behavioral abnormalities can be alleviated by treatment with the DRD2 agonist bromocriptine...Additionally, our findings suggest that the suppression of DRD2 may be regulated by enhanced RNA m6A modification following infection and may function through the DRD2/CRYAB/NF-κB signaling axis. These results emphasized the critical role of DRD2 in mediating T. gondii-induced neuroinflammation and neuropsychiatric abnormalities, providing novel insights into the development of therapeutic strategies for neuropsychiatric disorders associated with parasitic infections."

Journal • Preclinical • Alzheimer's Disease • Behavior Disorders • CNS Disorders • Cognitive Disorders • Depression • Infectious Disease • Inflammation • Mental Retardation • Psychiatry • CRYAB • DRD2

Vitamin D3 and Vitamin A Synergistically Prevent Visuospatial Memory Impairment in Mice Model of the Dopaminergic System Disorder. (PubMed, J Nutr Biochem) - "Dopaminergic system dysfunctions are linked to visuospatial memory impairment due to increased cytotoxicity, pro-inflammatory cytokines, oxidative stress, neural alterations, and reactive astrocyte expression, leading to reduced dopamine concentration in the PFC, HPC, visual cortex, and retina. Administration of vitamin A and D is more potent in providing a defensive mechanism by downregulating oxidative stress, reactive astrocytes, and their associated proinflammatory cytokines. All of which contribute to the regulation of dopamine levels."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • IL13 • IL4 • IL6 • TNFA

Course of Impulse Control Disorder in People Living with Parkinson's Disease: A Longitudinal Study on Dopamine Agonist Treatment (MDS Congress 2025) - "Studies strongly suggest that certain dopamine agonists (DA), such as pramipexole, increase the risk of ICD, while others, such as bromocriptine and rotigotine, might have a safer profile. The remission group demonstrated reduced total QUIP-RS scores and lower prevalence of specific compulsions, such as hypersexuality and compulsive shopping. Rotigotine was associated with a decreased likelihood of ICD, suggesting a safer alternative and highlighting the need for further research into its impact on ICD progression in PD. Table 1."

Longitudinal study • Observational data • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Recent advances in mucopolysaccharidosis IVA treatment. (PubMed, Orphanet J Rare Dis) - "Although enzyme replacement therapy (ERT) with elosulfase alfa is currently the only approved treatment, its clinical benefit on bone pathology is limited due to rapid clearance and poor penetration into avascular cartilage. Strategies to enhance enzyme stability and targeting, such as PEGylated hydrogels and extracellular vesicles, have shown promise in enhancing the biodistribution and stability of GALNS, while pharmacological chaperones, including ezetimibe, pranlukast, and bromocriptine, seem to stabilize GALNS in vitro...Importantly, recent evidence revealed that mitochondrial dysfunction in chondrocytes may contribute to the pathology of MPS IVA, uncovering new targets beyond GALNS enzyme activity recovery. This review highlights recent advances in the treatment of MPS IVA and discusses new directions to improve outcomes in MPS IVA treatment."

Journal • Review • Gene Therapies • Lysosomal Storage Diseases • Metabolic Disorders • Rare Diseases

DECODING DOPAMINERGIC MODULATION OF N-TYPE CA²⁺ CHANNELS IN SUBTHALAMIC NEURONS AND IMPLICATIONS FOR PATHOPHYSIOLOGICAL REGULATION IN PARKINSON'S DISEASE (WCN 2025) - "This study aims to decode the D2R-Cav2.2 interaction and its role in regulating resting membrane potential (RMP) stability and neuronal firing dynamics, identifying novel therapeutic strategies to restore basal ganglia function. A multi-scale computational framework integrated: Biophysical modeling of STN ion channels (Na⁺, K⁺, Cav2.2, Ca²⁺-activated K⁺) using Hodgkin-Huxley equations parameterized with PD-specific electrophysiological data; Kinetic modeling of D2R-GPCR cascades (D2R→Gi/o→AC5→cAMP→PKA) regulating Cav2.2 phosphorylation, informed by FRET-based cAMP biosensors; In silico pharmacology screening FDA-approved agents (e.g., bromocriptine, retigabine) to assess effects on RMP, AP frequency, and β-oscillations. This work identifies a dual-target mechanism wherein D2R-Cav2.2 coupling and K⁺ channel activation synergize to normalize STN excitability. KCNQ openers (e.g., retigabine) offer a non-dopaminergic strategy to mitigate RMP depolarization and..."

CNS Disorders • Movement Disorders • Parkinson's Disease • CACNA1B • CAV2

Storming Behind The Rash: Challenges in Diagnosing Paroxysmal Sympathetic Hyperactivity in an ICU patient with a Subdural Hematoma (ASA 2025) - "The patient was started on bromocriptine with improvement. This case highlights the diagnostic complexity in critically ill-patients with overlapping dermatologic, neurologic, and infectious processes, underscoring the importance of recognizing paroxysmal sympathetic hyperactivity in the absence of traumatic brain injury."

Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Dermatology • Epilepsy • Infectious Disease • Septic Shock • Vascular Neurology